SMT202200259T1 - Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata - Google Patents

Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata

Info

Publication number
SMT202200259T1
SMT202200259T1 SM20220259T SMT202200259T SMT202200259T1 SM T202200259 T1 SMT202200259 T1 SM T202200259T1 SM 20220259 T SM20220259 T SM 20220259T SM T202200259 T SMT202200259 T SM T202200259T SM T202200259 T1 SMT202200259 T1 SM T202200259T1
Authority
SM
San Marino
Prior art keywords
light chain
human animals
chain locus
lambda light
engineered immunoglobulin
Prior art date
Application number
SM20220259T
Other languages
English (en)
Italian (it)
Inventor
John Mcwhirter
Lynn Macdonald
Naxin Tu
Vera Voronina
Faith Harris
Andrew J Murphy
Chunguang Guo
Natasha Levenkova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SMT202200259T1 publication Critical patent/SMT202200259T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20220259T 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata SMT202200259T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417845P 2016-11-04 2016-11-04
US201762567932P 2017-10-04 2017-10-04
EP20180508.2A EP3766343B1 (en) 2016-11-04 2017-11-03 Non-human animals having an engineered immunoglobulin lambda light chain locus

Publications (1)

Publication Number Publication Date
SMT202200259T1 true SMT202200259T1 (it) 2022-07-21

Family

ID=62025924

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20220259T SMT202200259T1 (it) 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata
SM20200558T SMT202000558T1 (it) 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata
SM20250204T SMT202500204T1 (it) 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20200558T SMT202000558T1 (it) 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata
SM20250204T SMT202500204T1 (it) 2016-11-04 2017-11-03 Animali non umani aventi un locus di catena leggera di immunoglobulina lambda

Country Status (26)

Country Link
US (2) US10820582B2 (enExample)
EP (4) EP3766343B1 (enExample)
JP (5) JP6884860B2 (enExample)
KR (4) KR102658529B1 (enExample)
CN (2) CN109996441B (enExample)
AU (2) AU2017391167B2 (enExample)
BR (1) BR112019008675A2 (enExample)
CA (1) CA3038720A1 (enExample)
CY (2) CY1123491T1 (enExample)
DK (3) DK4082334T3 (enExample)
ES (3) ES2823305T3 (enExample)
FI (1) FI4082334T3 (enExample)
HR (3) HRP20201403T1 (enExample)
HU (3) HUE052087T2 (enExample)
IL (2) IL308197A (enExample)
LT (3) LT3766343T (enExample)
MA (2) MA53935A (enExample)
MX (2) MX385857B (enExample)
PL (3) PL3766343T3 (enExample)
PT (3) PT4082334T (enExample)
RS (3) RS66884B1 (enExample)
RU (2) RU2021129958A (enExample)
SG (2) SG11201903344XA (enExample)
SI (3) SI3766343T1 (enExample)
SM (3) SMT202200259T1 (enExample)
WO (1) WO2018128691A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2580017C2 (ru) 2010-07-26 2016-04-10 Трианни, Инк. Трансгенные животные и способы применения
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
PL2809150T3 (pl) * 2012-02-01 2020-04-30 Regeneron Pharmaceuticals, Inc. Humanizowane myszy wykazujące ekspresję łańcuchów ciężkich zawierających domeny VL
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
KR20250121150A (ko) 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3927153A1 (en) 2019-02-22 2021-12-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
JP7752536B2 (ja) * 2019-07-01 2025-10-10 トリアニ・インコーポレイテッド トランスジェニック哺乳動物およびその使用法
AU2021283564B2 (en) * 2020-06-02 2025-05-29 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
EP4262373A1 (en) 2020-12-16 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7758739B2 (ja) 2020-12-23 2025-10-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アンカー改変型抗体をコードする核酸およびその使用
AU2021409906A1 (en) 2020-12-23 2023-06-15 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
GB202217978D0 (en) * 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124967C (en) * 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
LT2346994T (lt) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in pelė, skirta chimerinių antikūnų gamybai
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
EP3028565B1 (en) * 2009-07-08 2017-09-27 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
SI2480676T1 (sl) 2010-06-22 2016-10-28 Regeneron Pharmaceuticals, Inc. Hibridna mišja lahka veriga
DK2813573T1 (da) 2011-02-25 2015-01-12 Regeneron Pharma ADAM6 mus
PL3216871T3 (pl) 2011-10-17 2022-03-21 Regeneron Pharmaceuticals, Inc. Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
MX378871B (es) * 2011-12-20 2025-03-10 Regeneron Pharma Ratones con cadena ligera humanizada.
RS57582B1 (sr) * 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
JP6475172B2 (ja) 2013-02-20 2019-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットの遺伝子組換え
US9788534B2 (en) * 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
WO2015049517A2 (en) * 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
BR112016028564A2 (pt) 2014-06-06 2018-01-30 Regeneron Pharma método para modificar um locus-alvo em uma célula.
MX384887B (es) 2014-06-23 2025-03-14 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017013104A2 (pt) 2014-12-19 2018-05-15 Regeneron Pharma métodos para modificar um locus genômico alvo em uma célula, para intensificar a recombinação homóloga em um locus genômico alvo em uma célula e para produzir uma geração f0 de um animal não humano.
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée

Also Published As

Publication number Publication date
MA44091A (fr) 2018-10-24
WO2018128691A1 (en) 2018-07-12
KR20190076024A (ko) 2019-07-01
DK3766343T3 (da) 2022-06-20
PL4082334T3 (pl) 2025-08-11
JP2020501516A (ja) 2020-01-23
EP4567119A3 (en) 2025-09-24
KR20240055863A (ko) 2024-04-29
US12433264B2 (en) 2025-10-07
CN114369157A (zh) 2022-04-19
LT3407709T (lt) 2020-10-12
AU2017391167B2 (en) 2024-02-15
RS66884B1 (sr) 2025-07-31
EP3766343A1 (en) 2021-01-20
IL266282A (en) 2019-06-30
EP3407709B1 (en) 2020-07-29
PL3766343T3 (pl) 2022-09-26
DK4082334T3 (da) 2025-06-02
KR20230020550A (ko) 2023-02-10
EP3407709B9 (en) 2021-10-06
FI4082334T3 (fi) 2025-06-10
MA53935A (fr) 2021-12-22
SG11201903344XA (en) 2019-05-30
AU2017391167A1 (en) 2019-05-30
HUE071595T2 (hu) 2025-09-28
EP4082334B1 (en) 2025-03-26
PL3407709T3 (pl) 2021-01-11
NZ753456A (en) 2021-08-27
US20180125043A1 (en) 2018-05-10
JP2022130725A (ja) 2022-09-06
EP3766343B1 (en) 2022-05-11
PT4082334T (pt) 2025-05-21
RS60886B1 (sr) 2020-11-30
RU2019112589A3 (enExample) 2021-03-30
MX2019005256A (es) 2019-08-05
PT3407709T (pt) 2020-08-20
KR102658529B1 (ko) 2024-04-19
JP7386292B2 (ja) 2023-11-24
LT3766343T (lt) 2022-06-10
SG10201913483XA (en) 2020-03-30
SMT202000558T1 (it) 2020-11-10
RU2757665C2 (ru) 2021-10-20
IL266282B2 (en) 2024-04-01
US20210029978A1 (en) 2021-02-04
LT4082334T (lt) 2025-05-26
CY1123491T1 (el) 2022-03-24
EP4082334A1 (en) 2022-11-02
RU2019112589A (ru) 2020-12-04
RS63390B1 (sr) 2022-08-31
ES2915609T3 (es) 2022-06-23
EP3407709A1 (en) 2018-12-05
CN109996441A (zh) 2019-07-09
CA3038720A1 (en) 2018-07-12
ES2823305T3 (es) 2021-05-06
CN109996441B (zh) 2022-02-08
MX2021010556A (es) 2021-10-01
KR102492433B1 (ko) 2023-01-30
HUE052087T2 (hu) 2021-04-28
AU2024200582A1 (en) 2024-03-28
MX385857B (es) 2025-03-18
SI3766343T1 (sl) 2022-06-30
HRP20201403T1 (hr) 2020-11-27
IL308197A (en) 2024-01-01
JP2025166207A (ja) 2025-11-05
IL266282B1 (en) 2023-12-01
HUE061980T2 (hu) 2023-09-28
JP2023053400A (ja) 2023-04-12
DK3407709T3 (da) 2020-08-31
BR112019008675A2 (pt) 2019-07-09
US10820582B2 (en) 2020-11-03
JP6884860B2 (ja) 2021-06-09
ES3035365T3 (en) 2025-09-02
KR102319069B1 (ko) 2021-11-01
JP2021090455A (ja) 2021-06-17
WO2018128691A8 (en) 2019-02-28
KR20210134059A (ko) 2021-11-08
PT3766343T (pt) 2022-05-30
SMT202500204T1 (it) 2025-07-22
CY1125474T1 (el) 2025-05-09
RU2021129958A (ru) 2021-11-02
SI3407709T1 (sl) 2020-10-30
HRP20250695T1 (hr) 2025-08-01
HRP20220888T1 (hr) 2022-10-28
SI4082334T1 (sl) 2025-06-30
EP4567119A2 (en) 2025-06-11

Similar Documents

Publication Publication Date Title
IL266282A (en) Non-human animals with a transgenic immunoglobulin light chain locus
IL274797A (en) Non-human animals with engineered immunoglobulin light chain and uses thereof
LT3597037T (lt) Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
HUE054612T2 (hu) Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
DK3129400T3 (da) Ikke-humane dyr med humaniserede Fc-gamma-receptorer
IL253579A0 (en) Anti-light chain substituent antibodies
IL268049A (en) Human antibodies from transgenic rodents with multiple immunoglobulin heavy chain LOCIs
SG10202006332PA (en) Transgenic rabbit with common light chain